Zoonovac-V Vaccine is a purified rabies vaccine formulated for human use, containing 2.5 IU of rabies antigen per dose. It is indicated for active immunization against rabies virus infection in individuals at risk of exposure, including those with occupational hazards or potential contact with rabid animals. The vaccine stimulates the immune system to produce protective antibodies, thereby preventing the onset of rabies, a fatal viral encephalitis. Zoonovac-V is administered intramuscularly following a prescribed immunization schedule, which may include pre-exposure prophylaxis for high-risk groups or post-exposure prophylaxis in conjunction with wound care and rabies immunoglobulin when indicated. The vaccine is produced using modern cell culture techniques ensuring high purity and safety. Common adverse effects are generally mild and transient, including localized pain, redness, and swelling at the injection site, with occasional systemic reactions such as fever or headache. Contraindications include hypersensitivity to any component of the vaccine. Careful adherence to dosing schedules and guidelines is essential for optimal immunogenicity and protection. Zoonovac-V Vaccine is a critical component in rabies prevention strategies, contributing significantly to reducing morbidity and mortality associated with this invariably fatal disease.